TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...
A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study. The experimental approach, which uses tiny capsules called small ...